Use of the drug angiovit in hemorrhagic fever with renal syndrome: evaluation of markers of vascular endothelial damage and kidney disfunction

Abstract

Hemorrhagic fever with renal syndrome (HFRS) is a common natural focal infectious disease in the Republic of Bashkortostan. Most patients are admitted to the clinic later than the 5th day of illness, when etiotropic drugs no longer show sufficient effectiveness, which determines the relevance of searching for new directions in the pathogenetic therapy of the disease.

The aim of the work is to evaluate the effect of the drug “Angiovit” on the course of HFRS, taking into account the determination of markers of vascular endothelial damage and impaired renal function.

Material and methods. The study included 91 male patients (age range 18–50 years) with a serologically confirmed diagnosis of HFRS. Among them, 38 patients received the Angiovit drug for 14 days in addition to standard therapy. Control group – 20 practically healthy volunteers. Blood biochemical parameters, levels of homocysteine, thrombomodulin and cystatin C were determined.

Statistical processing of the obtained results was carried out by parametric and non-parametric methods using software packages for mathematical and statistical analysis Biostatistica and Statistica 7.0.

Results. When prescribing the drug “Angiovit” to patients with various variants of the course of HFRS (moderate, severe and severe complicated), a statistically significant decrease in the serum concentration of homocysteine was noted, as well as a decrease in the serum concentration of thrombomodulin and cystatin C. A significant decrease in the level of serum creatinine and a reduction in the period of oliguria were established in comparison with the group of patients who received basic therapy.

Conclusion. The drug “Angiovit” can be used to reduce the level of homocysteine in the blood.

Keywords:hemorrhagic fever with renal syndrome; hyperhomocysteinemia; soluble thrombomodulin; cystatin C; Angiovit

Funding. The study did not have financial support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Concept and design – Latypova G.R., Murzabaeva R.T., Valishin D.A.; data collection – Latypova G.R., Lukmanova A.Kh.; statistical processing – Latypova G.R., Gilmanov A.Zh., Valishin D.A.; text writing, design – Latypova G.R., Murzabaeva R.T., Gilmanov A.Zh.; editing – Valishin D.A., Murzabaeva R.T., Gilmanov A.Zh.

For citation: Latypova G.R., Murzabaeva R.T., Valishin D.A., Gilmanov A.Zh., Lukmanova A.Kh. Use of the drug angiovit in hemorrhagic fever with renal syndrome: evaluation of markers of vascular endothelial damage and kidney disfunction. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (4): 99–105. DOI: https://doi.org/10.33029/2305-3496-2022-11-4-99-105

References

1.Valishin D.A. Hemorrhagic fever with renal syndrome in adults: clinical guidelines. Ufa: Publishing House of Bashkir State Medical University of the Ministry of Health of the Russian Federation, 2015: 74 p. (in Russian)

2. Sirotin B.Z. Hemorrhagic fever with renal syndrome. Khabarovsk, 1994: 304 p. (in Russian)

3. Baygil’dina A.A. Modern concepts of the pathogenesis of hemorrhagic fever with renal syndrome. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2014; 9 (1): 98–108. (in Russian)

4. Starostina V.I., Valishin D.A., Murzabaeva R.T., Shaykhullina L.R., Galieva A.T. Pathophysiological aspects of the pathogenesis of hemorrhagic fever with renal syndrome. Zabaykal’skiy meditsinskiy zhurnal [Transbaikal Medical Journal]. 2016; (4): 142–50. (in Russian)

5. Dmitriev A.S. Endothelial and renal dysfunction in hemorrhagic fever with renal syndrome: Abstract of Diss.: 14.01.09. Moscow, 2011: 25 p. (in Russian)

6. Mingazova E.M. Modern biomarkers in the monitoring of acute renal injury in hemorrhagic fever with renal syndrome: Abstract of Diss.: 14.01.09, 14.03.10. Saint Petersburg, 2017: 23 p. (in Russian)

7. Latypova G.R., Khunafina D.H., Valishin D.A., Khasanova G.M., Galieva G.A. Homocysteine as a marker of acute kidney and endothelial injury in patients with hemorrhagic fever with renal syndrome. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2019; 14 (6): 18–21. (in Russian)

8. Fahmy E.M., Elfayoumy N.M., Abdelalim A.M., Sharaf S.A.-A., Ismail R.Sh., Elshebawy H. Relation of serum levels of homocysteine, vitamin B12 and folate to cognitive functions in multiple sclerosis patients. Int J Neurosci. 2018; 128 (9): 835–41.

9. Serapinas D., Boreikaite E., Bartkeviciute A., Bandzeviciene R., Silkunas M., Bartkeviciene D. The importance of folate, vitamins B6 and B12 for the lowering of homocysteine concentrations for patients with recurrent pregnancy loss and MTHFR mutations. Reprod Toxicol. 2017; 72: 159–63.

10. Syrtlanova G.R. Pathogenetic role of homocysteine in hemorrhagic fever with renal syndrome. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy [Epidemiology and Infectious Diseases. Actual Issues]. 2012; (5): 16–8. (in Russian)

11. Dvoyrin V.V., Klimenkov A.A. Methods of controlled clinical trials. Moscow: Meditsina, 1985: 143 p. (in Russian)

12. Rebrova O.Yu. Statistical analysis of medical data. Using of the application package STATISTICA. Moscow: MediaSfera, 2002: 312 p. (in Russian)

13. Yang Z., Wang L., Zhang W., Wang X., Zhou Sh. Plasma homocysteine involved in methylation and expression of thrombomodulin in cerebral infarction. Biochem Biophys Res Commun. 2016; 473 (4): 1218–22.

14. Wu X., Zhang L., Miao Y., Yang J., Wang X., Wang Ch.-Ch., et al. Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis. Redox Biol. 2019; 20: 46–59.

15. Karazhanova L.K., Zhunuspekova A.S. Hyperhomocysteinemia as a risk factor for cardiovascular diseases (literature review). Nauka i zdravookhranenie [Science and Healthcare]. 2016; (4): 129–44. (in Russian)

16. Malinovskaya L.B., Selyuk V.M., Voytovich O.I., Kul’chicky B.B. The place of hyperhomocysteinemia in the pathogenesis of atherosclerosis and thrombosis. Serdtse i sosudy [Heart and Blood Vessels]. 2016; (3): 97–103. (in Russian)

17. Moiz B. Homocysteine as a biomarker for thrombosis: what is the learning curve? J Coll Physicians Surg Pak (JCPSP). 2017; 27 (3): 121–22.

18. Perna A.F., Ingrosso D. Homocysteine and chronic kidney disease: an ongoing narrative. J Nephrol. 2019; 32 (5): 673–5. DOI: https://doi.org/10.1007/s40620-019-00622-1.

19. Alekseev A.V., Gil’manov A.Zh., Gatiyatullina R.S., Rakipov I.G. Modern biomarkers of acute kidney injury. Prakticheskaya meditsina [Practical Medicine]. 2014; (3): 22–7. (in Russian)

20. Liu J., Quan J., Li Y., Wu Y., Yang L. Blood homocysteine levels could predict major adverse cardiac events in patients with acute coronary syndrome: a STROBE-compliant observational study. Medicine (Baltimore). 2018; 97 (40): e12626.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»